Description

Keytruda (pembrolizumab) concentrate for infusions 25 mg/ml. 4 ml. vial №1

Ingredients

Key Ingredient: Pembrolizumab

Dosage

Recommended Dosage: The recommended dose of Keytruda is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

Indications

Keytruda is indicated for:

• Treatment of advanced melanoma
• Non-small cell lung cancer
• Head and neck squamous cell cancer

Contraindications

Keytruda is contraindicated in individuals with:

• Severe hypersensitivity reactions to pembrolizumab
• Active autoimmune disease that has required systemic treatment

Directions

Administration: Keytruda should be administered by a healthcare professional. It is given as an intravenous infusion.

Scientific Evidence

Pharmacological Effects: Keytruda is a monoclonal antibody that works by blocking the PD-1 receptor, thereby enhancing the body’s immune response against cancer cells. This mechanism helps the immune system recognize and attack cancer cells more effectively.

Clinical Trials: Clinical trials have demonstrated the efficacy of Keytruda in various cancers, showing improved overall survival rates and durable responses in patients. For example, a study published in the New England Journal of Medicine showed significant improvement in progression-free survival in patients with advanced melanoma treated with pembrolizumab compared to chemotherapy.

Additional Information

Keytruda has revolutionized the treatment of certain cancers by harnessing the body’s immune system to fight the disease. Its targeted approach has shown promising results in clinical trials, making it a valuable option for patients with advanced cancers. It is important to discuss with your healthcare provider about the potential benefits and risks of Keytruda treatment.

As with any medication, Keytruda may cause side effects, including fatigue, rash, and immune-related adverse reactions. Close monitoring during treatment is essential to manage any potential complications effectively.